Micrima Limited announces first presentation of clinical data at ECR 2016
12 February 2016
Bristol, United Kingdom
Micrima Limited, the Bristol-based developer of the MARIA radiowave breast imaging system, today announced the first publication of clinical data from its ground-breaking device for breast cancer detection. Results from the first clinical trial of MARIA, conducted at Frenchay and Southmead Hospitals in Bristol, will be presented at the European Congress of Radiology (ECR), Vienna, Austria on Wednesday March 2nd 2016. The ECR is the annual meeting of the European Society of Radiology and is the preeminent radiological congress in Europe.
Speaking about this landmark publication Roy Johnson, Micrima’s Executive Chairman, said: “Micrima, along with our clinical partners, are delighted that the first ever public dissemination of MARIA’s excellent performance will be at the prestigious ECR. This demonstration of the system’s sensitivity in detecting breast cancer, particularly in the dense breast, is a significant milestone both for Micrima and, we hope, for the radiological community at large. These data represent the vanguard of a continually expanding program of clinical validation which supports the improving performance and functionality of this new radiowave-based breast imaging modality.”
Entitled “Radar imaging of breast lesions- a clinical evaluation and comparison” (no 2995), the work has been selected for an enhanced oral presentation and will be broadcast online as part of ECR Live, which had nearly 6000 ECR Live viewers in 2015 in addition to congress attendees. To listen to this presentation between 11.00-12.00 CET, follow the link:
Micrima’s Chief Technology Officer, Dr Peter Bannister, will be attending the congress and welcomes meetings with clinicians and others who are interested in learning more about MARIA as the company embarks on its program of EU clinical trials.
Micrima was founded in 2006 to develop and commercialise radiowave radar breast imaging technology, initially pioneered at the University of Bristol in the UK. The company’s MARIA system received European regulatory approval in 2015 and is currently deployed in pre-commercialisation clinical trials based at several breast cancer imaging centres throughout the UK.
For further information, please contact Micrima Executive Chairman Roy Johnson on 07769 883882
NOTES TO EDITORS:
Technology Venture Partners LLP (www.techvp.co.uk) is a venture capital fund management company based at the Innovation Centre at Bristol & Bath Science Park. TVP is authorised and regulated by the Financial Conduct Authority.
Swarraton Partners (www.swarraton.com) is a venture capital firm investing in European early stage technology companies based on world class IP.